CVX.PA Carvolix
- Market cap
- EUR 305M
- P/E
- -
- P/B
- 7.00x
- ROE
- -128.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CVX.PA undervalued?
Graham numberThe Graham number of Carvolix cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Carvolix fundamental analysis
No fundamental analysis for Carvolix yet.
Carvolix stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Carvolix
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILO…
Full company profileCarvolix financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Carvolix annual financial statements
| Item | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.00K | 43.0K | 1.43M | 824K | 1.45M | 1.34M | 1.22M | 4.12M | - | - |
| Gross Profit | -3.80M | -10.9M | -831K | -2.44M | -1.29M | -1.10M | -1.20M | -9.27M | -2.19M | -9.13M |
| Operating Income | -7.09M | -10.3M | -15.3M | -13.0M | -13.2M | -11.9M | -13.1M | -15.7M | -18.0M | -62.3M |
| EBITDA | -6.94M | -9.90M | -12.6M | -10.5M | -11.0M | -13.3M | -13.0M | -13.4M | -15.8M | -53.2M |
| Net Income | -5.84M | -8.75M | -16.6M | -14.3M | -14.8M | -15.2M | -15.7M | -14.7M | -25.0M | -55.5M |
| EPS | -0.48 | -0.72 | -0.89 | -0.77 | -0.80 | -0.81 | -0.54 | -0.37 | -0.63 | -1.00 |
| Balance Sheet | ||||||||||
| Total Assets | 61.7M | 67.4M | 65.3M | 64.8M | 70.0M | 60.0M | 56.6M | 60.9M | 47.8M | 99.7M |
| Total Liabilities | 2.85M | 6.00M | 34.3M | 29.5M | 26.5M | 26.2M | 25.2M | 30.6M | 42.3M | 56.3M |
| Shareholders' Equity | 58.9M | 61.4M | 31.0M | 35.3M | 43.5M | 33.8M | 31.5M | 30.3M | 5.55M | 43.4M |
| Cash & Short-term Investments | 1.63M | 4.88M | 2.13M | 5.65M | 11.4M | 2.58M | 1.66M | 6.62M | 1.76M | 7.02M |
| Total Debt | 159K | 2.85M | 24.2M | 20.8M | 19.8M | 17.7M | 17.1M | 16.3M | 24.0M | 19.5M |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -10.8M | -11.4M | -8.94M | -12.4M | -11.1M | -12.1M | -11.3M | -11.6M | -52.4M |
| Capital Expenditure | 0.00 | 263K | 196K | 304K | 334K | 146K | 184K | 147K | 116K | 568K |
| Free Cash Flow | - | -11.1M | -11.6M | -9.24M | -12.7M | -11.2M | -12.2M | -11.5M | -11.7M | -53.0M |
| Ratios | ||||||||||
| ROE | -9.9% | -14.3% | -53.6% | -40.6% | -34.0% | -45.0% | -49.7% | -48.7% | -449.8% | -128.1% |
| ROA | -9.5% | -13.0% | -25.4% | -22.1% | -21.2% | -25.4% | -27.6% | -24.2% | -52.2% | -55.7% |
| Net Profit Margin | -194,566.7% | -20,353.5% | -1,160.9% | -1,737.7% | -1,021.4% | -1,137.2% | -1,278.8% | -357.9% | - | - |
| Debt to Equity | 0.00x | 0.05x | 0.78x | 0.59x | 0.45x | 0.52x | 0.54x | 0.54x | 4.33x | 0.45x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Carvolix dividends
Carvolix has not paid dividends in the last 9 fiscal years.
Who owns Carvolix
- Insiders 18.27%
- Institutions 65.62%
- Public & others 16.11%
- Shares outstanding 62.2M
- Free float 284K
Carvolix company profile
- Company name
- Carvolix
- Ticker
- CVX.PA
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 102
- Fiscal year end
- December
- Address
- 900 rue Andre Ampere, Aix-en-Provence, France, 13290
- Phone
- 33 4 42 95 12 20
- Website
- carvolix.eu
About Carvolix
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantation; TAVIPILOT Robot, mitral valve repair and replacement solutions; MITRAPILOT, a biomimetic transcatheter mitral valve; and Artedrone, an implantable artificial urinary sphincter. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.
Carvolix management
10- Mr. Sebastien Ladet Ph.D.Chief Executive Officer
- Mr. Christophe de VregilleChief Financial Officer
- Ms. Celine BuardHead of marketing & EU Commercialization
- Melanie CantalHuman Resources Manager
- Mr. Nicolas Barry Delongchamps M.D.Chief Medical Officer & Member of Scientific Advisory Board
- Prof. Francois Laborde M.D., Ph.D.Chief Surgical Officer
- Mr. Olivier PierronDeputy Chief Executive Officer · born 1969
- Mr. Benjamin Renault Ph.D.Chief Development Officer
- Dr. Howard C. Herrmann M.D.Chief Medical Officer
- Pierre Berthet-Rayne Ph.D.Chief Technology Officer Robotics